Matthew Taylor
Stock Analyst at Jefferies
(3.21)
# 1,067
Out of 4,736 analysts
178
Total ratings
58.56%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $87.34 | +17.93% | 2 | Jan 8, 2025 | |
| ABT Abbott Laboratories | Maintains: Hold | $120 → $125 | $116.79 | +7.03% | 12 | Oct 17, 2024 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $69.97 | +0.04% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $276.08 | -19.23% | 14 | Aug 9, 2024 | |
| INMD InMode | Downgrades: Hold | $21 → $19 | $16.96 | +12.03% | 6 | Jul 23, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $88.38 | -14.01% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $2.96 | +4,122.97% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $176.07 | -31.28% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $5.17 | +170.79% | 1 | Jan 19, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $35.30 | +27.48% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.91 | -44.78% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $25.12 | +110.99% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $13.91 | +72.54% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $395.85 | -12.85% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $110.52 | +17.63% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $268.20 | -14.24% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $17.29 | +15.67% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $70.95 | +19.80% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $92.41 | -18.84% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $247.79 | -1.13% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $88 | $79.50 | +10.69% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $31.48 | +96.95% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $182.45 | +15.10% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $11.61 | +3.36% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $86.32 | +44.81% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $100.91 | -50.45% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $604.12 | -65.24% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $31 | $4.68 | +562.39% | 5 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $49.21 | +95.08% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $3.91 | +79.03% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $240.37 | +10.66% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $11.94 | +34.00% | 2 | Jul 19, 2017 |
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $87.34
Upside: +17.93%
Abbott Laboratories
Oct 17, 2024
Maintains: Hold
Price Target: $120 → $125
Current: $116.79
Upside: +7.03%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $69.97
Upside: +0.04%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $276.08
Upside: -19.23%
InMode
Jul 23, 2024
Downgrades: Hold
Price Target: $21 → $19
Current: $16.96
Upside: +12.03%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $88.38
Upside: -14.01%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $2.96
Upside: +4,122.97%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $176.07
Upside: -31.28%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $5.17
Upside: +170.79%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $35.30
Upside: +27.48%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.91
Upside: -44.78%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $25.12
Upside: +110.99%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $13.91
Upside: +72.54%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $395.85
Upside: -12.85%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $110.52
Upside: +17.63%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $268.20
Upside: -14.24%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $17.29
Upside: +15.67%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $70.95
Upside: +19.80%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $92.41
Upside: -18.84%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $247.79
Upside: -1.13%
Oct 12, 2022
Initiates: Buy
Price Target: $88
Current: $79.50
Upside: +10.69%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $31.48
Upside: +96.95%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $182.45
Upside: +15.10%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $11.61
Upside: +3.36%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $86.32
Upside: +44.81%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $100.91
Upside: -50.45%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $604.12
Upside: -65.24%
Oct 12, 2022
Initiates: Underperform
Price Target: $31
Current: $4.68
Upside: +562.39%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $49.21
Upside: +95.08%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $3.91
Upside: +79.03%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $240.37
Upside: +10.66%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $11.94
Upside: +34.00%